Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Gastroenterología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 2
ClinicalTrials.gov
An Open-Label Re-Treatment Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C
INTERVENTIONAL
Inicio: 1 de sept de 2011
ID: NCT01428063
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Open-Label, Single Arm, Rollover Trial of TMC435 in Combination With Peginterferon Alpha-2A and Ribavirin for HCV Genotype-1 Infected Subjects Who Participated in the Placebo Group of a Phase II/III TMC435 Study, or Who Received DAA Treatment in a Tibotec-Sponsored Phase I Study.
INTERVENTIONAL
Inicio: 1 de dic de 2011
ID: NCT01323244
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression
INTERVENTIONAL
Inicio: 14 de mar de 2022
ID: NCT05111626
Completado
Fase 2
ClinicalTrials.gov
Standard Training Versus Intensive Training for HIIP Delivery System Usage in Insulin-Naïve Patients With Type 2 Diabetes Mellitus
INTERVENTIONAL
Inicio: 1 de nov de 2004
ID: NCT00099515
Desconocido
ClinicalTrials.gov
Risk Factors and Outcomes of Pyogenic Liver Abscess in Adult Liver Recipients: A Match Case Control Study
OBSERVATIONAL
Inicio: 22 de nov de 2016
ID: NCT03064685
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Patients With Moderately to Severely Active Ulcerative Colitis
INTERVENTIONAL
Inicio: 17 de sept de 2024
ID: NCT06589986
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis
INTERVENTIONAL
Inicio: 13 de jun de 2019
ID: NCT03945188
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer
INTERVENTIONAL
Inicio: 14 de jul de 2016
ID: NCT02743494
Activo, no recluta
Fase 2
ClinicalTrials.gov
A 52-week Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2a Study Assessing Safety and Efficacy of Brivekimig, a Dual Anti-TNF-α and Anti-OX40L NANOBODY® Molecule, for Preservation of Pancreatic β-cell Function in Adults and Adolescents With Recently Diagnosed Type 1 Diabetes
INTERVENTIONAL
Inicio: 28 de feb de 2025
ID: NCT06812988
Reclutando
ClinicalTrials.gov
Institutional Registries of Rare Diseases at Hospital Italiano de Buenos Aires (HIBA)
OBSERVATIONAL
Inicio: 1 de jul de 2024
ID: NCT06573723
Completado
Fase 1
ClinicalTrials.gov
Autologous Bone Marrow Transplanted Via Transendocardial Catheter to Chronic Myocardial Infarct Border Zone
INTERVENTIONAL
Inicio: 1 de dic de 2005
ID: NCT00507468
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.
INTERVENTIONAL
ID: NCT00035035
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Long-term Efficacy and Safety of ABX464 25 mg or 50 mg Once Daily as a Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
INTERVENTIONAL
Inicio: 16 de ene de 2023
ID: NCT05535946
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Randomized, Double-blind, Active Controlled, Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI With the Fixed Dose Dual Combination of FF/VI, Administered Once-daily Via a Dry Powder Inhaler in Subjects With Inadequately Controlled Asthma
INTERVENTIONAL
Inicio: 13 de oct de 2016
ID: NCT02924688
Completado
Fase 3
ClinicalTrials.gov
A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects With Ulcerative Colitis and Crohn's Disease
INTERVENTIONAL
Inicio: 15 de abr de 2016
ID: NCT02620046
Completado
Fase 2
ClinicalTrials.gov
A Phase 2a, Double-Blind, Randomized, Active Controlled, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Bezafibrate Administered in Combination With Obeticholic Acid in Subjects With Primary Biliary Cholangitis
INTERVENTIONAL
Inicio: 21 de mar de 2022
ID: NCT05239468
Terminado
Fase 2
ClinicalTrials.gov
A Randomized, Open-label Phase II Multicenter Study Evaluating the Efficacy of Oral Everolimus Alone or in Combination With Pasireotide LAR i.m. in Advanced Progressive Pancreatic Neuroendocrine Tumors (PNET) - The COOPERATE-2 Study
INTERVENTIONAL
Inicio: 1 de jun de 2011
ID: NCT01374451
Completado
Fase 2
ClinicalTrials.gov
A Multicenter, Single-Treatment Study to Assess the Safety and Tolerability of Lyophilized Lucinactant in Adults With COVID-19 Associated Acute Lung Injury
INTERVENTIONAL
Inicio: 5 de ene de 2021
ID: NCT04389671
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
INTERVENTIONAL
Inicio: 18 de jul de 2018
ID: NCT03519945
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
INTERVENTIONAL
Inicio: 4 de sept de 2024
ID: NCT06528314
Anterior
1
...
12
13
14
...
434
Siguiente
Filtros